Stephen K Tahir
Overview
Explore the profile of Stephen K Tahir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
5301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tahir S, Calvo E, Carneiro B, Yuda J, Shreenivas A, Jongen-Lavrencic M, et al.
Blood
. 2023 Jan;
141(17):2114-2126.
PMID: 36720090
Activation of apoptosis in malignant cells is an established strategy for controlling cancer and is potentially curative. To assess the impact of concurrently inducing the extrinsic and intrinsic apoptosis-signaling pathways...
2.
Tong Y, Florjancic A, Clark R, Lai C, Mastracchio A, Zhu G, et al.
ACS Med Chem Lett
. 2021 Jul;
12(7):1108-1115.
PMID: 34267880
Cyclin-dependent kinase 9 (CDK9) is a serine/threonine kinase involved in the regulation of transcription elongation. An inhibition of CDK9 downregulates a number of short-lived proteins responsible for tumor maintenance and...
3.
Phillips D, Buchanan F, Cheng D, Solomon L, Xiao Y, Xue J, et al.
Cancer Res
. 2021 Mar;
81(12):3402-3414.
PMID: 33687950
TRAIL can activate cell surface death receptors, resulting in potent tumor cell death via induction of the extrinsic apoptosis pathway. Eftozanermin alfa (ABBV-621) is a second generation TRAIL receptor agonist...
4.
Wang L, Doherty G, Judd A, Tao Z, Hansen T, Frey R, et al.
ACS Med Chem Lett
. 2020 Oct;
11(10):1829-1836.
PMID: 33062160
Herein we describe the discovery of A-1331852, a first-in-class orally active BCL-X inhibitor that selectively and potently induces apoptosis in BCL-X-dependent tumor cells. This molecule was generated by re-engineering our...
5.
Phillips D, Jin S, Gregory G, Zhang Q, Xue J, Zhao X, et al.
Leukemia
. 2019 Dec;
34(6):1646-1657.
PMID: 31827241
MCL-1 is one of the most frequently amplified genes in cancer, facilitating tumor initiation and maintenance and enabling resistance to anti-tumorigenic agents including the BCL-2 selective inhibitor venetoclax. The expression...
6.
Smith M, Tahir S
Methods Mol Biol
. 2018 Dec;
1877:163-172.
PMID: 30536005
Flow cytometry is a powerful technique for the detection and quantification of cell surface and intracellular proteins. It enables the ability to measure the expression levels of specific proteins in...
7.
Tahir S, Smith M, Hessler P, Rapp L, Idler K, Park C, et al.
BMC Cancer
. 2017 Jun;
17(1):399.
PMID: 28578655
Background: Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior therapy. It...
8.
Lam L, Lin X, Faivre E, Yang Z, Huang X, Wilcox D, et al.
Mol Cancer Ther
. 2017 May;
16(8):1511-1520.
PMID: 28468776
Ten percent to 15% of all lung cancers are small-cell lung cancer (SCLC). SCLC usually grows and metastasizes before it is diagnosed and relapses rapidly upon treatment. Unfortunately, no new...
9.
Smith M, Chyla B, McKeegan E, Tahir S
Cytometry B Clin Cytom
. 2016 May;
92(5):331-339.
PMID: 27177607
Background: We have developed a quantitative fluorescence cytometry (QFCM) method that can be used to measure BCL-2 family member proteins in cell lines and clinical samples. We described the validation...
10.
Ackler S, Oleksijew A, Chen J, Chyla B, Clarin J, Foster K, et al.
Pharmacol Res Perspect
. 2015 Oct;
3(5):e00178.
PMID: 26516589
The Bcl-2 family inhibitors venetoclax and navitoclax demonstrated potent antitumor activity in chronic lymphocytic leukemia patients, notably in reducing marrow load and adenopathy. Subsequent trials with venetoclax have been initiated...